<unk>  is indicated for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or curative radiation.
Cemiplimab
Regdanvimab
Atoltivimab
Sotrovimab
Lirentelimab
Obiltoxaximab
Nirsevimab
Odesivimab